HOME » News & Media

    Vyome Bioscience to present data at ASM Microbe Conference 2016, Boston.


    15th June 2016. Vyome Biosciences, a clinical stage biopharmaceutical company pioneering innovation driven dermatology R&D of novel platform technologies and drugs that target the critical unmet needs of antimicrobial resistance of opportunistic pathogens of the skin, announced today that research findings for the Company’s advanced anti-fungal platform technology, Molecular Replacement Therapy (MRT), will be presented through poster at American Society of Microbiology (ASM) Microbe 2016 Conference, taking place in Boston, MA, on June 16-20, 2016.

    Trichophyton spp. are dermatophyte fungi that invade and grow in the keratin of skin, hair and nails, and are responsible for various skin infections like ring worm, athlete's foot etc. Depending on the site of the infection, different topical antimycotics show varied degree of therapeutic benefits. In recent years, there have also been reports of drug resistance in dermatophytes that further aggravate the clinical manifestation. In pursuit of addressing these unmet clinical needs, Vyome has developed a platform technology, MRT, which not only imparts enhanced fungal killing ability to a known agent, but also allows its higher retention in the skin. Therefore, a two-pronged effect, an immediate impact of the formulation on fungus residing in the upper layers of the skin, followed by a long term sustained effect of higher retained amount of actives on fungus residing in deeper layers of the skin, becomes evident.

    ASM Microbe 2016 Poster Presentation Details:



      Robust Potentiation of Known Antimycotic Agents with Molecular Replacement Therapy (MRT) for the Topical Treatment of Tinea Infections


      S. Ghosh, R. S. Patel, S. P. Kaur, S. Sadhasivam, K. K. Aavula, M. Sinha, A. Bhattacharyya, D. Kumar, A. Jain, S. Ghosh, S. Sengupta; Vyome Biosciences Pvt. Ltd, Delhi, India, Brigham & Women's Hosp., Cambridge, MA

    Date & Time:

      June 19, 2016, 12:30 - 2:30 PM EDT


      Session 276 - Sunday Late-Breaker Poster Presentations
    The poster abstract will be available at ASM Microbe 2016 website.

    "There is an urgent need for novel anti-fungal platform technologies that can overcome the rising unmet need of resistance in existing treatment classes like azoles. We believe that the promising data on Vyome’s innovative anti-fungal technology platform, MRT, will provide a strong base for the continued development of MRT as a novel platform for potentiating known anti-fungals for the treatment of fungal infections including Tinea infections," said N. Venkat, Co-Founder & CEO, Vyome Biosciences.

    Visit: www.vyome.in
    Copyright © 2021 Vyome Biosciences Private Limited.

    Copyright © 2015 Vyome Therapeutics Inc. All rights reserved.